Salute e Benessere

COSRX Announces Exclusive Deals for Amazon Prime Day 2024 in the UK

Among the highlighted deals are: Among the highlighted deals are: "We are thrilled to participate in Amazon Prime Day, offering our customers exclusive access to some of our most beloved skincare products," said a representative from COSRX. "This is a fantastic opportunity for both our loyal customers and newcomers alike to experience the transformative power of COSRX skincare at unbeatable prices." Prime members can take advantage of these special deals by visiting COSRX's…
PR Newswire
15/07/2024

AstraZeneca Closes Acquisition of Amolyt Pharma

announcedacquisition by the global pharmaceutical company, AstraZeneca, has closed. The acquisition bolsters the Alexion, AstraZeneca Rare Disease late-stage pipeline and expands on its bone metabolism franchise with the notable addition of eneboparatide (AZP-3601), a Phase III investigational therapeutic peptide with a novel mechanism of action designed to meet key therapeutic goals for hypoparathyroidism. In patients with hypoparathyroidism, a deficiency in parathyroid hormone (PTH)...
Nasdaq GlobeNewswire
15/07/2024

CMR Surgical appoints Daniel Moore as Non-Executive Chairman

CMR Surgical appoints Daniel Moore as Non-Executive ChairmanMedical technology veteran with over 35 years of senior leadership experience Cambridge, UK – 15 July 2024, 07:00 (BST).CMR Surgical (CMR or 'the Company'), the global surgical robotics business, today announces the appointment of Daniel (Dan) Moore as Non-Executive Chairman of the Board of Directors, effective immediately.Dan Moore is a seasoned executive with over 35 years of both executive and board leadership...
Nasdaq GlobeNewswire
15/07/2024

Nyxoah Appoints Scott Holstine as Chief Commercial Officer

Nyxoah Appoints Scott Holstine as Chief Commercial OfficerMont-Saint-Guibert, Belgium – July 15, 2024, 8:00am CET / 2:00am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH)(“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced the appointment of Scott Holstine as Chief Commercial Officer. In this role, Scott will lead the commercial operations of Nyxoah...
Nasdaq GlobeNewswire
15/07/2024

Rznomics Inc. Secures Australian Clinical Trial Notification for RHO-targeted…

RZ-004, AAV vector encoding a rhodopsin RNA-targeting trans-splicing ribozyme along with wild type rhodopsin, specifically targets and reprograms pathogenic mutant Rhodopsin mRNA into normal Rhodopsin mRNA, thereby leading to the therapeutic effect. Since RZ-004 targets conservative upstream region of the rhodopsin mutations, all different types of mutations in each patient could be treated with one therapy. RZ-004, AAV vector encoding a rhodopsin RNA-targeting trans-splicing ribozyme along...
PR Newswire
15/07/2024

Camurus announces positive Phase 3 results from the ACROINNOVA 2 study of…

The primary endpoint was safety over 52 weeks of study treatment. Octreotide SC depot was well tolerated with a long-term safety profile consistent with that of SoC with first generation somatostatin receptor ligands (SRL), extended-release octreotide and lanreotide, with no new safety signals. The most common adverse events (AEs) were mild to moderate injection site reactions and gastrointestinal events. There were no cases of severe AEs related to octreotide SC depot. One patient had a…
PR Newswire
15/07/2024

Crossject to attend H.C. Wainwright 26th Annual Global Investment Conference

Dijon, France, July 15 th2024, 07:30 CET -- Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharma company in advanced phases of development and registration for ZEPIZURE®, its emergency treatment for the management of epileptic crises based on its award-winning needle-free auto-injector ZENEO®, announces it will attend the H.C. Wainwright 26th Annual Global Investment Conference, taking place in New York September 9-11, 2024. About Crossject Crossject SA...
Nasdaq GlobeNewswire
15/07/2024

Addex Presents Positive Results from GABAB PAM Cough Program at the Thirteenth…

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, July 15, 2024- Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that positive results from the Company's novel gamma-aminobutyric acid sub-type B receptor (GABAB) positive allosteric modulator (PAM) chronic cough program will be presented during the...
Nasdaq GlobeNewswire
15/07/2024

BioSenic S.A. : Transparency notification received from Véronique Pomi  

PRESS RELEASE – REGULATED INFORMATION Article 14 of the Law of 2 May 2007 on disclosure of major holdings Mont-Saint-Guibert, Belgium, July 12, 2024, 6pm CEST –BIOSENIC (Euronext Brussels and Paris: BIOS), the clinical-stage company specializing in serious autoimmune and inflammatory diseases and cell therapy, today announces that it has received a transparency notification from Ms Véronique Pomi. The notifications details can be found below and can be consulted on the website of...
Nasdaq GlobeNewswire
12/07/2024

Global Soap and Detergent Market Manufacturers Innovate to Meet Eco-Friendly…

Reports on competitive analyses encompass company overviews, financial performances, product portfolios, and strategies of key players in the Soap & Detergent market. To assess strengths and weaknesses, a comprehensive SWOT analysis was conducted, while a PESTLE analysis was carried out to understand the impact of macroeconomic factors on the market. Also, the report includes detailed analyses of investments made by market players to enhance their global presence. Reports on competitive...
PR Newswire
12/07/2024

Global High-Throughput Screening (HTS) Market to Reach USD 50.2 Billion by 2029…

Browse in-depth TOC on "High-Throughput Screening (HTS) Market". Browse in-depth TOC on "High-Throughput Screening (HTS) Market". 732 - Tables 58 - Figures 577 - Pages Dominance of Consumables Segment in HTS Market In 2023, the consumables segment accounted for the largest share of the global HTS market, driven by the extensive use of reagents and assay kits crucial for HTS processes. The segment's growth is fueled by rising R&D spending among pharmaceutical companies...
PR Newswire
12/07/2024

3D Cell Culture Market to Transcend USD 11.79 Billion Valuation by 2031, Rising…

Download a detailed overview: Download a detailed overview: https://www.skyquestt.com/sample-request/3d-cell-culture-market 3D Cell Culture Market Overview: Segments covered in 3D Cell Culture Market are as follows: Request Free Customization of this report: https://www.skyquestt.com/speak-with-analyst/3d-cell-culture-market High Use of Scaffold-based Technology in Regenerative Medicine and Tissue Engineering Applications Growing use of cells in different...
PR Newswire
12/07/2024

PPG Biosensors Market to be dominated by Smartwatches Segment to reach USD…

The information for the PPF Biosensors Market report was collected using primary and secondary research methods, which were combined to make the report reliable. The primary research conducted includes the questionnaire distribution, surveys, and phone interviews with industry experts, market leaders, marketing professionals, and entrepreneurs. The bottom-up methodology has been used to estimate the global and regional market size. SWOT analysis was used to provide the strengths and weaknesses…
PR Newswire
12/07/2024

Endo Files Registration Statement with SEC, Advancing Planned Move to NYSE

Endo anticipates trading of its common stock on the NYSE will begin later in 2024, subject to the SEC declaring the Registration Statement effective and any other required approvals and customary conditions. Endo anticipates trading of its common stock on the NYSE will begin later in 2024, subject to the SEC declaring the Registration Statement effective and any other required approvals and customary conditions. Shares of Endo's common stock currently trade on the OTCQX ®Best Market. U.S...
PR Newswire
12/07/2024

IM Cannabis Shares Commence Trading on 6:1 Consolidated Basis

After giving effect to the Consolidation, the Common Shares were reduced from 13,394,136 to 2,232,357 Common Shares. No fractional Common Shares were issued in connection with the Consolidation. Instead, all fractional Common Shares equal to or greater than one-half resulting from the Consolidation were rounded to the next whole number, otherwise, the fractional Common Share were cancelled. The exercise price and/or conversion price and number of Common Shares issuable under any of the Company's…
PR Newswire
12/07/2024

Charlotte Casebourne Stock moves on from Theolytics to next entrepreneurial…

Mike Grey commented: "On behalf of the board and Theolytics' investors we would like to extend our heartfelt appreciation to Charlotte. Without her, Theolytics wouldn't be in the strong position the company finds itself in today. Under Charlotte's leadership, over $40m of dilutive and non-dilutive capital was raised, and in only seven years the company has advanced into the clinic. We respect her decision to pursue new entrepreneurial endeavors, and wish her the very best. I look forward to…
PR Newswire
12/07/2024

Shenzhen Hosts the 2nd AGP&DTx Summit Forum: Advancing Digital Therapeutics in…

At the conference, Professor Andrej Janež, Head of the Department of Endocrinology at the Ljubljana University Medical Centre in Slovenia, highlighted China's advancements in AGP clinical practice. He remarked, "They've developed an AGP training program, and they're moving into the area of researching and using AI to enhance diagnosis and guide treatment decisions, leading to better diabetes care and facilitating AGP applications." At the conference, ProfessorAndrej Janež, Head of…
PR Newswire
12/07/2024

TXOne Networks Welcomes Stephen Driggers as New Chief Revenue Officer

"We are very excited about everything that Stephen is bringing to our company as our new CRO," said Dr. Terence Liu, Chief Executive Officer, TXOne Networks. "He is an inspiring leader with proven results in a variety of environments, and his professionalism and personal integrity are obvious. His contributions to TXOne Networks and our customers will be far-reaching." "We are very excited about everything that Stephen is bringing to our company as our new CRO,"…
PR Newswire
12/07/2024

"Salvează o inimă" Association innovates fundraising campaigns by integrating AI…

"Artificial intelligence helps us make a real-time analysis of the situation in order to make rapid adjustments to the fundraising strategy, but it also allows us to offer donors information about the efficiency of the campaigns they have contributed to," Vlad Plăcintă, president of the "Salvează o inimă" Association said. "Artificial intelligence helps us make a real-time analysis of the situation in order to make rapid adjustments to the fundraising strategy, but it…
PR Newswire
12/07/2024

XRP Healthcare LLC Successfully Registers Trademark in the UAE, Strengthening…

Registration in Ugandais crucial for branding its future healthcare establishments across Africa with the XRP Healthcare logo, ensuring consistency and recognition. The new trademark in the UAE further solidifies XRP Healthcare's presence and safeguards its brand in a key international market. Registration inUgandais crucial for branding its future healthcare establishments acrossAfricawith the XRP Healthcare logo, ensuring consistency and recognition. The new trademark in the UAE...
PR Newswire
12/07/2024

Addex To Present at the Thirteenth London International Cough Symposium (13th…

Geneva, Switzerland, July 12, 2024-Addex Therapeutics(SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that Mikhail Kalinichev, Head of Translational Science, will present at the Thirteenth London International Cough Symposium taking place July 18 - 19, 2024 at Imperial College in London, U.K.In his presentation, scheduled for 12:00 CEST /...
Nasdaq GlobeNewswire
12/07/2024

Leqembi approved for the treatment of Alzheimer's disease in Israel

Leqembi selectively binds to soluble amyloid-beta (Aβ) aggregates (protofibrils[2]), as well as insoluble Aβ aggregates (fibrils) which are a major component of Aβ plaques in AD, thereby reducing both Aβ protofibrils and Aβ plaques in the brain. Leqembi is the world's first approved treatment shown to reduce the rate of disease progression and to slow cognitive and functional decline through this mechanism. Leqembi selectively binds to soluble amyloid-beta (Aβ) aggregates (protofibrils [2] ),...
PR Newswire
12/07/2024

Molecular Glues Clinical Trial Pipeline Appears Robust With 10+ Key Pharma…

Key Takeaways from the Molecular Glues Competitive Landscape Report Key Takeaways from the Molecular Glues Competitive Landscape Report Request a sample and discover the recent advances in molecular glues treatment @ Molecular Glues Competitive Landscape Report Molecular Glues Overview Molecular glues are a novel class of small molecules that facilitate the interaction between proteins, leading to the degradation or modulation of target proteins that are typically difficult to drug...
PR Newswire
11/07/2024

ESP prostheses training program

Press release Ecully, July 11, 2024 – 6.30 p.m. Spineway organizes hands-on training on total disc replacement with its ESP prostheses at IRCAD in StrasbourgThe Spineway Group, a specialist in innovative implants for the treatment of severe spine disorders, organized a hands-on training workshop entitled “Hands-on Total Disc Replacement featuring ESP technology” at the Institut de Recherche contre les Cancers de l'Appareil Digestif (IRCAD) in Strasbourg on June 28, 2024...
Nasdaq GlobeNewswire
11/07/2024
Altri  Comunicati